Core Points - The controlling shareholder, actual controller, and chairman of Shanhe Pharmaceutical Auxiliary, Mr. Yin Zhenglong, has passed away [1] Company Summary - Shanhe Pharmaceutical Auxiliary (300452.SZ) has announced the death of its chairman, which may impact the company's leadership and strategic direction [1]

Core Viewpoint - The announcement details the passing of Yin Zhenglong, the controlling shareholder and chairman of Shanhe Pharmaceutical Auxiliary, which may impact the company's governance and future direction [1] Company Information - Yin Zhenglong passed away on August 26, 2025, at the age of 60 [1] - He held approximately 63.06 million shares, representing 26.9% of the company's total shares [1] - The company will handle the transfer of shares according to relevant laws and regulations [1] Management Transition - Following the passing of Yin Zhenglong, Song Daocai, a board member and general manager, has been appointed to temporarily assume the roles of chairman and legal representative [1] - This interim arrangement will remain until a new chairman is elected by the board [1]

Core Points - The company announced the passing of its founder and chairman, Mr. Yin Zhenglong, on August 26, 2025, at the age of 60 [1][2] - Mr. Yin was instrumental in the development of the Chinese pharmaceutical industry, focusing on domestic pharmaceutical excipients and achieving a transition from following to competing internationally [2] - The company will ensure that the board of directors remains functional and will not be affected by Mr. Yin's passing, with interim leadership provided by Mr. Song Daocai [3] Company Overview - Mr. Yin Zhenglong held 63,057,454 shares in the company, representing a significant portion of the total shares [2] - The company has a structured plan to elect a new chairman in accordance with legal regulations and its articles of association [3] - Mr. Song Daocai, currently the general manager, will temporarily assume the role of chairman until a new chairman is elected [3][5] Leadership Background - Mr. Song Daocai, aged 56, has extensive experience within the company, having held various positions since 2008, including production director and general manager [5] - He has a background in economic management and is a licensed pharmacist and engineer [5]

安徽山河药用辅料股份有限公司 证券代码:300452 证券简称:山河药辅 公告编号：2025-049 债券代码:123199 债券简称:山河转债 公司全体董事、高级管理人员和全体员工，对尹正龙先生为公 司付出的无数心血和做出的巨大贡献表示最衷心感谢，对尹正龙先生 的逝世致以沉痛哀悼和怀念，并向尹正龙先生的家人致以深切慰问。 尹正龙先生持有公司股份 63,057,454 股，占公司股份总额的 26.90%，为公司控股股东、实际控制人。尹正龙先生所持的公司股 份将按相关法律法规办理相关手续，公司将根据后续事项进展情况及 时履行信息披露义务。 尹正龙先生的逝世不会导致公司董事会成员人数低于法定人数， 不会影响公司董事会的正常运作。公司经营管理团队正常履职，各项 经营业务活动不会受到影响。公司董事长职位出现空缺，根据有关法 律法规和《公司章程》的规定，公司将尽快完成董事补选、选举董事 长等工作。经全体董事推举，现由公司董事、总经理宋道才先生（简 历详见附件）暂行行使公司董事长和法定代表人职责，直至公司董事 会选举出新的董事长之日止。 关于公司控股股东、实际控制人、董事长逝世的公告 本公司及董事会全体成员保证本公告内容 ...

Core Points - The company held its seventh meeting of the sixth board of directors on August 26, 2025, with all eight directors present, confirming compliance with relevant laws and regulations [1][2]. - The board approved the 2025 semi-annual report, affirming that the report accurately reflects the company's actual situation without any false statements or omissions [1][2]. - The board also approved a special report on the management and use of raised funds for the first half of 2025, confirming compliance with regulatory requirements [2]. Summary by Sections - **Meeting Details** - The meeting was attended by all eight directors, and the notice was sent out on August 17, 2025 [1]. - The meeting was chaired by Mr. Yin Zhenglong [1]. - **Approval of Semi-Annual Report** - The board reviewed and approved the 2025 semi-annual report, ensuring its authenticity and completeness [1][2]. - Voting results showed unanimous support with 8 votes in favor [2]. - **Approval of Fund Management Report** - The board approved a special report on the management and use of raised funds, confirming adherence to relevant regulations [2]. - This report was also reviewed and approved by the audit committee prior to the board meeting [2].

Group 1 - The company, Shanhe Pharmaceutical, announced that its sixth board of directors held the seventh meeting, where it approved the proposal regarding the full text and summary of the 2025 semi-annual report [2]

（编辑 何成浩） 证券日报网讯 8月26日晚间，山河药辅发布公告称，2025年半年度公司实现营业收入470，839，549.60 元，同比增长4.65%；归属于上市公司股东的净利润为93，035，152.04元，同比下降2.61%。 ...

Core Insights - The company reported a revenue of 471 million yuan for the first half of the year, reflecting a year-on-year growth of 4.65% [1] - The net profit attributable to shareholders decreased by 2.61% to 93.0352 million yuan [1] - The basic earnings per share stood at 0.4 yuan [1]

Group 1 - Sichuan Gold achieved a net profit of 209 million yuan in the first half of 2025, a year-on-year increase of 48.41% [1] - Hai Xin Co. reported a net profit of 108 million yuan, up 5.62% year-on-year, despite a revenue decline of 8.35% [1] - Shanhe Pharmaceutical Auxiliary's net profit decreased by 2.61% to 93.04 million yuan, with a revenue increase of 4.65% [2] Group 2 - Donghua Software's net profit fell by 15.78% to 244 million yuan, with a slight revenue decline of 1.76% [2] - Zhongyuan Haike reported a significant net profit drop of 91.21% to 9.83 million yuan, alongside a revenue decrease of 9.97% [3] - Xingxin New Materials experienced a net profit decline of 21.72% to 33.64 million yuan, with a minimal revenue growth of 0.02% [4] Group 3 - Longban Media's net profit increased by 13.28% to 120 million yuan, despite a revenue drop of 24.01% [6] - Guangge Technology reported a net loss of 31.38 million yuan, worsening from a loss of 20.17 million yuan in the previous year, with a revenue increase of 71.44% [7] - Ge Ke Wei's net profit decreased by 61.59% to 29.76 million yuan, despite a revenue growth of 30.33% [8] Group 4 - Shaoyang Hydraulic's net profit fell by 31.68% to 7.11 million yuan, with a revenue decline of 12.84% [9] - Qianjiang Biochemical achieved a net profit of 107 million yuan, a year-on-year increase of 30.24%, despite a revenue decline of 9.64% [10] - Jianhui Information's net profit dropped by 82.99% to 502.52 million yuan, with a revenue increase of 9.03% [11] Group 5 - Nobon Co. reported a net profit of 65.33 million yuan, up 48.33% year-on-year, with a revenue increase of 33.35% [12] - Proya's net profit increased by 13.80% to 799 million yuan, with a revenue growth of 7.21% [13] - Huayuan Holdings reported a net loss of 22.48 million yuan, improving from a loss of 39.2 million yuan in the previous year, with a revenue decline of 94.74% [15] Group 6 - Chihong Zn & Ge's net profit increased by 3.27% to 932 million yuan, with a revenue growth of 7.67% [17] - Dae Oriental's net profit decreased by 45.33% to 59.04 million yuan, with a revenue decline of 5.20% [19] - Zhongnong Lihua's net profit fell by 10.06% to 142 million yuan, despite a revenue increase of 3.27% [20] Group 7 - Triangle Tire's net profit decreased by 35.31% to 396 million yuan, with a revenue decline of 4.50% [21] - Lianchuang Optoelectronics reported a net profit of 263 million yuan, up 15.18% year-on-year, with a revenue increase of 6.51% [22] - Taijing Technology's net profit fell by 61.59% to 22.04 million yuan, despite a revenue growth of 16.73% [23] Group 8 - Congsheng Co. announced plans to establish a wholly-owned subsidiary with an investment of 5 million yuan [24] - Yilian Network's net profit decreased by 8.84% to 1.24 billion yuan, with a slight revenue decline of 0.64% [25] - Weichuang Electric's net profit increased by 4.87% to 141 million yuan, with a revenue growth of 16.39% [26] Group 9 - Liuyuan Chemical reported a net loss of 149 million yuan, worsening from a profit of 29.37 million yuan in the previous year, with a revenue increase of 3.10% [28] - Luxshare Precision achieved a net profit of 6.644 billion yuan, a year-on-year increase of 23.13%, with a revenue growth of 20.18% [29] - Jiangfeng Electronics reported a net profit of 253 million yuan, up 56.79% year-on-year, with a revenue increase of 28.71% [30] Group 10 - Hongqiao Technology reported a net loss of 22.97 million yuan, worsening from a profit of 21.96 million yuan in the previous year, with a revenue decline of 11.76% [31] - Hong Sifang's net profit decreased by 47.10% to 43.97 million yuan, with a revenue decline of 8.18% [32] - Huaxia Happiness reported a net loss of 6.827 billion yuan, worsening from a loss of 4.849 billion yuan in the previous year, with a revenue decline of 50.90% [35] Group 11 - Watson Bio's net profit decreased by 74.69% to 43.16 million yuan, with a revenue decline of 19.47% [37] - Huayang Lianzhong's controlling shareholder plans to increase its stake by 1% to 2% [39] - Lanhua Ketech's net profit decreased by 89.58% to 57.48 million yuan, with a revenue decline of 26.05% [41] Group 12 - Aike Optoelectronics reported a net profit increase of 127.40% to 36.04 million yuan, with a revenue growth of 64.39% [43] - Guojia Automobile's net profit decreased by 14.32% to 21.3 million yuan, with a revenue decline of 11.64% [44] - Yingjia Gongjiu's net profit decreased by 18.19% to 1.13 billion yuan, with a revenue decline of 16.89% [46] Group 13 - China Shipbuilding Technology reported a net loss of 574 million yuan, worsening from a loss of 81.71 million yuan in the previous year, with a revenue increase of 30.79% [48] - Dayang Electric's net profit increased by 34.41% to 602 million yuan, with a revenue growth of 7.66% [49] - Shoukai Co. reported a net loss of 1.839 billion yuan, improving from a loss of 1.948 billion yuan in the previous year, with a revenue increase of 105.19% [51]

格隆汇8月26日丨山河药辅(300452.SZ)公布2025年半年度报告，上半年公司实现营业收入4.71亿元，同 比增长4.65%；归属于上市公司股东的净利润9303.52万元，同比下降2.61%；归属于上市公司股东的扣 除非经常性损益的净利润8475.40万元，同比增长6.05%；基本每股收益0.40元。 ...